Regulatory
Published · Updated · 1 min read
MHRA: new antidepressant measures and withdrawal of the IXCHIQ vaccine authorisation
What it means for practice
Consider the MHRA updates on communicating the risks of suicidal thoughts and persistent sexual dysfunction with antidepressants. Report suspected adverse reactions through the Yellow Card scheme.
Summary
The MHRA Safety Roundup for October 2026 covers updates on antidepressants, the IXCHIQ chikungunya vaccine and medical devices. Key topics include communication about medicine risks, the benefit–risk balance of vaccination and concerns that could affect antifungal treatment.
Antidepressants and the IXCHIQ vaccine
New measures for antidepressants aim to improve communication about the risks of suicidal thoughts and persistent sexual dysfunction. The UK marketing authorisation for IXCHIQ has been withdrawn because of an unfavourable benefit–risk balance.
Medical devices
The roundup highlights adsorption of echinocandins onto PAN-based membranes during continuous renal replacement therapy. This could potentially reduce the efficacy of antifungal treatment. Quality control issues involving Nova Biomedical StatStrip ketone test strips are also noted.
Adverse reaction reporting
As part of #MedSafetyWeek, the MHRA also emphasises the importance of reporting adverse reactions through the Yellow Card scheme.
Source
-
MHRA. MHRA Safety Roundup: October 2026.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
